Evidence map›Paper›PMID 33200304›Full record

Observational studyEuropean journal of pediatrics2021

Compassionate use of remdesivir in children with COVID-19.

Ana Méndez-Echevarría, Antonio Pérez-Martínez, Luis Gonzalez Del Valle, María Fátima Ara, Susana Melendo, Marta Ruiz de Valbuena, Jose Luis Vazquez-Martinez, Antonio Morales-Martínez, Agustín Remesal, Kinga Amália Sándor-Bajusz and 2 more

Open access · greenAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in European journal of pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
1.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Remdesivir in COVID-19: A Focus on Pediatric Cardiac Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Review
  6. Article
  7. Article
  8. Remdesivir: treatment of COVID-19 in special populations.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Ana Méndez-EchevarríaPaediatric Infectious Diseases Department, Translational Research Network in Paediatric Infectious Diseases (RITIP), La Paz University Hospital, Paseo de la Castellana 261, 28046, Madrid, Spain. amendezes@yahoo.es.ORCID https://orcid.org/0000-0002-7455-9080
Antonio Pérez-MartínezPaediatric Hemato-Oncology Department, Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy, La Paz University Hospital, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Luis Gonzalez Del VallePharmacy Department, La Paz University Hospital, Madrid, Spain.
María Fátima AraDepartment of Paediatrics and Neonatology, Quironsalud Madrid University Hospital, Madrid, Spain.
Susana MelendoPaediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron (HUVH). Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Marta Ruiz de ValbuenaPediatric Pulmunology Unit, La Paz University Hospital, Madrid, Spain.
Jose Luis Vazquez-MartinezPaediatric Intensive Care Unit, Ramon y Cajal Universitary Hospital, Madrid, Spain.
Antonio Morales-MartínezPaediatric Intensive Care Unit, Universitary Regional Málaga Hospital, Málaga, Spain.
Agustín RemesalPaediatric Rheumatology Unit, La Paz University Hospital, Madrid, Spain.
Kinga Amália Sándor-BajuszDepartment of Paediatrics, University of Pécs Medical School, Pécs, Hungary.
Fernando CabañasDepartment of Neonatology, Quironsalud Madrid University Hospital and Biomedical Research Foundation, La Paz University Hospital Madrid, Madrid, Spain.
Cristina CalvoPaediatric Infectious Diseases Department, Translational Research Network in Paediatric Infectious Diseases (RITIP), La Paz University Hospital, Paseo de la Castellana 261, 28046, Madrid, Spain.
Hospital Universitario La Paz · ESHospital Universitario Quirónsalud Madrid · ESHospital La Paz Institute for Health Research · ESHospital Regional Universitario de Málaga · ESUniversity of Pecs · HUVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Children represent a minority of total COVID-19 cases, but studies have reported severe disease and death in pediatric patients. Remdesivir (RDV) has recently demonstrated promising results in adults with COVID-19, but few data have been reported to date in children.A nationwide multicenter observational study was conducted on children with confirmed SARS-CoV-2 receiving compassionate treatment with RDV in Spain. Eight patients were included in the study, four infants and four older children [median age 5 years old; IQR 4 months-11.6 years old]. Half of them had complex underlying medical conditions, and the rest were mostly infants (3/4). Six out of eight children needed Pediatric Intensive Care Unit Admission. No RDV-related adverse outcomes were observed in our patients. Seven have reached successful clinical outcome, but one patient with serious clinical status died due to complications. However, she received RDV very late after the first COVID-19 symptom.Conclusions: In our cohort, most of the patients achieved successful clinical outcome, without observing adverse events. Clinical trials of RDV therapy for children with COVID-19 are urgently needed, to assess the safety, tolerability, efficacy, and pharmacokinetics of RDV in children, as this could be an effective treatment in severe cases. What is Known: • Remdesivir has not been approved to treat COVID-19 in children under 12 years old, although the drug is currently being prescribed in critically ill children. • Remdesivir has recently demonstrated promising results in adults with COVID-19, but few data have been reported to date in paediatric population. What is New: • We report a multicentre cohort of children with confirmed SARS-CoV-2 and severe COVID-19 disease receiving remdesivir during the first month of the pandemic in Spain. • No remdesivir-related adverse outcomes were observed in most of the cases. Seven patients reached successful clinical outcome, and one died due to complications (bacterial sepsis).

Indexed as

Compassionate Use TrialsCOVID-19 Drug TreatmentAdenosine MonophosphateAdolescentAlanineAntiviral AgentsChildChild, PreschoolCritical IllnessFemaleHumansInfantMaleSeverity of Illness IndexSpainTreatment OutcomeAdenosine MonophosphateAlanineAntiviral AgentsremdesivirChildrenCOVID-19InfantRemdesivirSARS-CoV-2

Identifiers

PMID33200304
PMCPMC7668659
OpenAlexW3098785905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.